Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66


Editorial: Baclofen in the Treatment of Alcohol Use Disorder.

de Beaurepaire R, Heydtmann M, Agabio R.

Front Psychiatry. 2019 May 15;10:338. doi: 10.3389/fpsyt.2019.00338. eCollection 2019. No abstract available.


The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.

de Beaurepaire R, Sinclair JMA, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Jaury P, Lingford-Hughes AR, Morley KC, Müller CA, Owens L, Pastor A, Paterson LM, Pélissier F, Rolland B, Stafford A, Thompson A, van den Brink W, Leggio L, Agabio R.

Front Psychiatry. 2019 Jan 4;9:708. doi: 10.3389/fpsyt.2018.00708. eCollection 2018. Review.


A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder.

de Beaurepaire R.

Front Psychiatry. 2018 Oct 17;9:506. doi: 10.3389/fpsyt.2018.00506. eCollection 2018. Review.


Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.

Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Heydtmann M, Jaury P, Lingford-Hughes AR, Morley KC, Müller CA, Owens L, Pastor A, Paterson LM, Pélissier F, Rolland B, Stafford A, Thompson A, van den Brink W, de Beaurepaire R, Leggio L.

Lancet Psychiatry. 2018 Dec;5(12):957-960. doi: 10.1016/S2215-0366(18)30303-1. Epub 2018 Nov 6. No abstract available.


[Predictive factors of seclusion duration in patients hospitalized in psychiatry settings. A prospective multisite study in the DTRF Paris-Sud].

Costemale-Lacoste JF, Cerboneschi V, Trichard C, De Beaurepaire R, Villemain F, Metton JP, Debacq C, Ghanem T, Martelli C, Baup E, Loeb E, Hardy P; le DTRF Paris-Sud.

Encephale. 2019 Apr;45(2):107-113. doi: 10.1016/j.encep.2018.01.005. Epub 2018 Mar 24. French.


Nicotine enhances alcohol intake and dopaminergic responses through β2* and β4* nicotinic acetylcholine receptors.

Tolu S, Marti F, Morel C, Perrier C, Torquet N, Pons S, de Beaurepaire R, Faure P.

Sci Rep. 2017 Mar 23;7:45116. doi: 10.1038/srep45116.


Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.

Artiges E, Leroy C, Dubol M, Prat M, Pepin A, Mabondo A, de Beaurepaire R, Beaufils B, Korwin JP, Galinowski A, D'Albis MA, Santiago-Ribeiro MJ, Granger B, Tzavara ET, Martinot JL, Trichard C.

Schizophr Bull. 2017 Sep 1;43(5):1134-1142. doi: 10.1093/schbul/sbw192.


Treatment of binge eating disorder with high-dose baclofen: a case series.

de Beaurepaire R, Joussaume B, Rapp A, Jaury P.

J Clin Psychopharmacol. 2015 Jun;35(3):357-9. doi: 10.1097/JCP.0000000000000332. No abstract available.


Colitis possibly induced by quetiapine.

de Beaurepaire R, Trinh I, Guirao S, Taieb M.

BMJ Case Rep. 2015 Feb 26;2015. pii: bcr2014207912. doi: 10.1136/bcr-2014-207912.


The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series.

de Beaurepaire R.

Front Psychiatry. 2014 Oct 10;5:143. doi: 10.3389/fpsyt.2014.00143. eCollection 2014.


[Off-label prescriptions in public psychiatric hospital practice].

Andréoli L, Gaudoneix M, Beauverie P, de Beaurepaire R.

Therapie. 2013 Nov-Dec;68(6):347-59. doi: 10.2515/therapie/2013054. Epub 2013 Nov 11. French.


[Somatic comorbidity of schizophrenia].

de Beaurepaire R.

Rev Prat. 2013 Mar;63(3):344-5. French. No abstract available.


Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients.

de Beaurepaire R.

Front Psychiatry. 2012 Dec 3;3:103. doi: 10.3389/fpsyt.2012.00103. eCollection 2012.


Abstinence and 'low-risk' consumption 1 year after the initiation of high-dose baclofen: a retrospective study among 'high-risk' drinkers.

Rigal L, Alexandre-Dubroeucq C, de Beaurepaire R, Le Jeunne C, Jaury P.

Alcohol Alcohol. 2012 Jul-Aug;47(4):439-42. doi: 10.1093/alcalc/ags028. Epub 2012 Mar 19.


Is smoking linked to positive symptoms in acutely ill psychiatric patients?

de Beaurepaire R, Rat P, Beauverie P, Houery M, Niel P, Castéra S, Dagorne O, Espaze R, Giroult P, Mahuzier G, Matheron I, Padovani P, Poisson N, Richier JP, Rocher J, Ruetsh O, Touzeau D, Visinoni A, Molimard R.

Nord J Psychiatry. 2012 Sep;66(4):225-31. doi: 10.3109/08039488.2011.610468. Epub 2011 Sep 12.


Smoke extracts and nicotine, but not tobacco extracts, potentiate firing and burst activity of ventral tegmental area dopaminergic neurons in mice.

Marti F, Arib O, Morel C, Dufresne V, Maskos U, Corringer PJ, de Beaurepaire R, Faure P.

Neuropsychopharmacology. 2011 Oct;36(11):2244-57. doi: 10.1038/npp.2011.112. Epub 2011 Jun 29.


Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.

Victoriano M, de Beaurepaire R, Naour N, Guerre-Millo M, Quignard-Boulangé A, Huneau JF, Mathé V, Tomé D, Hermier D.

Brain Res. 2010 Sep 2;1350:167-75. doi: 10.1016/j.brainres.2010.05.060. Epub 2010 Jun 4.


Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons.

Arib O, Rat P, Molimard R, Chait A, Faure P, de Beaurepaire R.

Eur J Pharmacol. 2010 Mar 10;629(1-3):47-52. doi: 10.1016/j.ejphar.2009.12.012. Epub 2009 Dec 21.


"Where do auditory hallucinations come from?"--a brain morphometry study of schizophrenia patients with inner or outer space hallucinations.

Plaze M, Paillère-Martinot ML, Penttilä J, Januel D, de Beaurepaire R, Bellivier F, Andoh J, Galinowski A, Gallarda T, Artiges E, Olié JP, Mangin JF, Martinot JL, Cachia A.

Schizophr Bull. 2011 Jan;37(1):212-21. doi: 10.1093/schbul/sbp081. Epub 2009 Aug 7.


Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

Victoriano M, Hermier D, Even PC, Fromentin G, Huneau JF, Tomé D, de Beaurepaire R.

Psychopharmacology (Berl). 2009 Sep;206(1):167-76. doi: 10.1007/s00213-009-1593-5. Epub 2009 Jul 2.


Supplemental Content

Loading ...
Support Center